PracticeUpdate: Haematology & Oncology

ASCO 2016 13

First Line. First Fight. Set goals. Target control. Expect results.

FIRST LINE TAFINLAR ® + MEKINIST ® … confidence in FIGHTING BRAFV600+ stage III (unresectable) and metastatic melanoma 1,2

SET long-term goals for your BRAFV600+ patients TAFINLAR ® + MEKINIST ® significantly improved OS vs BRAFi monotherapy across 3 pivotal, head-to-head trials 3–7 Overall survival: 44% of patients alive at 3-years with 58% of these patients still receiving TAFINLAR ® + MEKINIST ® treatment 7

TARGET first line disease control

7out of 10 patients achieved a complete or partial response 3–5 9 out of 10

patients experienced clinical benefit with TAFINLAR ® + MEKINIST ® vs BRAFi monotherapy 3–5

OS: Overall survival, BRAFi: BRAF inhibitor

Indication: trametinib in combination with dabrafenib is indicated for the treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma. Confirmation of BRAF V600 mutation with approved/validated test required. Contraindications: trametinib in combination with dabrafenib — hypersensitivity to the actives, or excipients. See full PI^. Precautions: trametinib in combination with dabrafenib — non-cutaneous malignancies, haemorrhage, cardiomyopathy, ocular adverse events, retinal pigment epithelial detachment, retinal vein occlusion, uveitis, iritis, interstitial lung disease, pneumonitis, pyrexia, serious non-infectious febrile events, serious skin toxicity, cutaneous squamous cell carcinoma, new primary melanoma, non-cutaneous malignancy, renal failure, hepatic events, pancreatitis, hyperglycaemia, effects on fertility, pregnancy (category D), lactation, paediatric use, and use in elderly. See full PI^. Interactions: trametinib is unlikely to interact with CYP isoenzymes or transporters. Small decrease (16 %) in trametinib bioavailability with dabrafenib co-administration; dabrafenib — strong inhibitors or inducers of CYP2C8 or CYP3A4, proton pump inhibitors, medicinal products affected by induction of CYP3A4, CYP2C9, CYP2B6, CYP2C8, CYP2C19, UGT and transporters, hormonal contraceptives, warfarin, statins and OATP1B1 or OATP1B3 substrates. See full PI. Adverse Events: trametinib in combination with dabrafenib — very common: urinary tract infection (UTI), neutropenia, dizziness, haemorrhage, night sweats, muscle spasms, rash, dry skin, dermatitis acneiform, actinic keratosis, erythema, pruritus, decreased appetite, dehydration, headache, cough, oropharyngeal pain, diarrhoea, nausea, vomiting, constipation, abdominal pain, dry mouth, pyrexia, chills, fatigue, peripheral edema, arthralgia, myalgia, back pain, muscle spasm, pain in extremity, anaemia, insomnia, increased ALT/AST, increased alkaline phosphatase (ALP) and hyperbilirubinemia. Common — thrombocytopenia, hyponatraemia, hypotension, gamma-glutamyltransferase (GGT) increase, hyperhidrosis, rhabdomyolysis and QT prolongation. See full PI^. Dosage and Administration: trametinib in combination with dabrafenib — dabrafenib 150 mg (as two 75 mg capsules) twice daily (total daily dose 300 mg), approximately 12 hours between doses, at least one hour before or at least two hours after a meal, at similar times every day; trametinib 2 mg once daily, on an empty stomach, taken orally at the same time each day, with either the morning or evening dose of dabrafenib. Dose adjust according to each PI. Trametinib dose adjustments below 1 mg not recommended. Dabrafenib dose adjustments below 50 mg twice daily not recommended; daily dose should not exceed 150 mg twice daily. See full PI^. ^When trametinib is used in combination with dabrafenib, refer to the full individual PI documents. (mektaf100715mv2) References: 1. Tafinlar (dabrafenib). Product Information. 2. Mekinist (trametinib). Product Information. 3. Long G et al. Lancet 2015; 386(9992): 444–51. 4. Robert C et al. N Engl J Med 2015; 372: 30–9. 5. Flaherty K et al. N Engl J Med 2012; 367:1694–1703 6. Long G et al. J Clin Oncol 2016; 34(8): 871–8. 7. Flaherty KT et al. Oral presentation at ASCO 2016: June 3–7, Chicago, Illinois. Novartis Pharmaceuticals Australia Pty Ltd, ABN 18 004 244 160, 54 Waterloo Road, Macquarie Park, NSW 2113. Phone (02) 9805 3555. Item No.: MEL0190. Date of preparation: September 2016. Tafinlar ® and Mekinist ® are registered trademarks of Novartis AG.

DECEMBER 2016